Cargando…

CAG预激方案联合沙利度胺、干扰素、重组人IL-2治疗难治复发性急性髓系白血病疗效分析

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial office of Chinese Journal of Hematology 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7343089/
https://www.ncbi.nlm.nih.gov/pubmed/27093999
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2016.04.017
_version_ 1783555692748079104
collection PubMed
description
format Online
Article
Text
id pubmed-7343089
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Editorial office of Chinese Journal of Hematology
record_format MEDLINE/PubMed
spelling pubmed-73430892020-07-16 CAG预激方案联合沙利度胺、干扰素、重组人IL-2治疗难治复发性急性髓系白血病疗效分析 Zhonghua Xue Ye Xue Za Zhi 短篇论著 Editorial office of Chinese Journal of Hematology 2016-04 /pmc/articles/PMC7343089/ /pubmed/27093999 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2016.04.017 Text en 2016年版权归中华医学会所有 http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under a Creative Commons Attribution 3.0 License (CC-BY-NC). The Copyright own by Publisher. Without authorization, shall not reprint, except this publication article, shall not use this publication format design. Unless otherwise stated, all articles published in this journal do not represent the views of the Chinese Medical Association or the editorial board of this journal.
spellingShingle 短篇论著
CAG预激方案联合沙利度胺、干扰素、重组人IL-2治疗难治复发性急性髓系白血病疗效分析
title CAG预激方案联合沙利度胺、干扰素、重组人IL-2治疗难治复发性急性髓系白血病疗效分析
title_full CAG预激方案联合沙利度胺、干扰素、重组人IL-2治疗难治复发性急性髓系白血病疗效分析
title_fullStr CAG预激方案联合沙利度胺、干扰素、重组人IL-2治疗难治复发性急性髓系白血病疗效分析
title_full_unstemmed CAG预激方案联合沙利度胺、干扰素、重组人IL-2治疗难治复发性急性髓系白血病疗效分析
title_short CAG预激方案联合沙利度胺、干扰素、重组人IL-2治疗难治复发性急性髓系白血病疗效分析
title_sort cag预激方案联合沙利度胺、干扰素、重组人il-2治疗难治复发性急性髓系白血病疗效分析
topic 短篇论著
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7343089/
https://www.ncbi.nlm.nih.gov/pubmed/27093999
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2016.04.017
work_keys_str_mv AT cagyùjīfāngànliánhéshālìdùàngànrǎosùzhòngzǔrénil2zhìliáonánzhìfùfāxìngjíxìngsuǐxìbáixuèbìngliáoxiàofēnxī
AT cagyùjīfāngànliánhéshālìdùàngànrǎosùzhòngzǔrénil2zhìliáonánzhìfùfāxìngjíxìngsuǐxìbáixuèbìngliáoxiàofēnxī
AT cagyùjīfāngànliánhéshālìdùàngànrǎosùzhòngzǔrénil2zhìliáonánzhìfùfāxìngjíxìngsuǐxìbáixuèbìngliáoxiàofēnxī
AT cagyùjīfāngànliánhéshālìdùàngànrǎosùzhòngzǔrénil2zhìliáonánzhìfùfāxìngjíxìngsuǐxìbáixuèbìngliáoxiàofēnxī
AT cagyùjīfāngànliánhéshālìdùàngànrǎosùzhòngzǔrénil2zhìliáonánzhìfùfāxìngjíxìngsuǐxìbáixuèbìngliáoxiàofēnxī
AT cagyùjīfāngànliánhéshālìdùàngànrǎosùzhòngzǔrénil2zhìliáonánzhìfùfāxìngjíxìngsuǐxìbáixuèbìngliáoxiàofēnxī
AT cagyùjīfāngànliánhéshālìdùàngànrǎosùzhòngzǔrénil2zhìliáonánzhìfùfāxìngjíxìngsuǐxìbáixuèbìngliáoxiàofēnxī
AT cagyùjīfāngànliánhéshālìdùàngànrǎosùzhòngzǔrénil2zhìliáonánzhìfùfāxìngjíxìngsuǐxìbáixuèbìngliáoxiàofēnxī
AT cagyùjīfāngànliánhéshālìdùàngànrǎosùzhòngzǔrénil2zhìliáonánzhìfùfāxìngjíxìngsuǐxìbáixuèbìngliáoxiàofēnxī